Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator
- PMID: 8187237
- DOI: 10.1016/0009-3084(94)90159-7
Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator
Abstract
Molecular assembly of plasminogen and tissue-type plasminogen activator (t-PA) at the surface of fibrin results in the generation of fibrin-bound plasmin and thereby in the dissolution of a clot. This mechanism is triggered by specific interactions of intra-chain surface lysine residues in fibrin with the kringle domains of plasminogen, and is further amplified via the interaction of plasminogen kringles with the carboxy-terminal lysine residues of fibrin that are exposed by plasmin cleavage. By virtue of its marked homology with plasminogen, apo(a), the specific apolipoprotein component of Lp(a), may bind to the lysine sites available for plasminogen on the surface of fibrin and thereby interfere with the fibrinolytic process. A sensitive solid-phase fibrin system, which allows the study of plasminogen activation at the plasma fibrin interface and makes feasible the analysis of products bound to fibrin, has been used to investigate the effects of Lp(a) on the binding of plasminogen and its activation by fibrin-bound t-PA. Plasma samples from human subjects with high levels of Lp(a) were studied. We have established that Lp(a) binds to the fibrin surface and thereby competes with plasminogen (Ki = 44 nM) so as to inhibit its activation. We have further shown that Lp(a) blocks specifically carboxy-terminal lysine residues on the surface of fibrin. To further explore the role of apo(a) on the Lp(a) fibrin interactions, we have performed ligand-binding studies using a recombinant form of apo(a) that contains 17 kringle 4-like units. We have shown that recombinant apo(a) binds specifically to fibrin (Kd = 26 +/- 8 nM, Bmax = 26 +/- 2 fmol/well) and that this binding increases upon treatment of the fibrin surface with plasmin (Kd = 8 +/- 4 nM, Bmax = 115 +/- 14 fmol/well). Altogether, our results indicate clearly that binding of native Lp(a) through this mechanism may impair clot lysis and may favor the accumulation of cholesterol in thrombi at sites of vascular injury.
Similar articles
-
Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.Biochemistry. 1992 Jul 14;31(27):6333-9. doi: 10.1021/bi00142a024. Biochemistry. 1992. PMID: 1627572
-
Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.Arterioscler Thromb. 1991 May-Jun;11(3):629-38. doi: 10.1161/01.atv.11.3.629. Arterioscler Thromb. 1991. PMID: 1827591
-
Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces.Chem Phys Lipids. 1994 Jan;67-68:353-62. doi: 10.1016/0009-3084(94)90157-0. Chem Phys Lipids. 1994. PMID: 8187235 Review.
-
Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains.J Biol Chem. 2003 Sep 26;278(39):37154-9. doi: 10.1074/jbc.M305154200. Epub 2003 Jul 9. J Biol Chem. 2003. PMID: 12853452
-
Inhibition of fibrinolysis by lipoprotein(a).Ann N Y Acad Sci. 2001;936:261-75. doi: 10.1111/j.1749-6632.2001.tb03514.x. Ann N Y Acad Sci. 2001. PMID: 11460483 Review.
Cited by
-
Thrombus composition and thrombolysis resistance in stroke.Res Pract Thromb Haemost. 2023 May 16;7(4):100178. doi: 10.1016/j.rpth.2023.100178. eCollection 2023 May. Res Pract Thromb Haemost. 2023. PMID: 37538503 Free PMC article.
-
Endogenous fibrinolysis inhibitors in acute coronary syndrome.Am Heart J Plus. 2021 Oct 7;10:100058. doi: 10.1016/j.ahjo.2021.100058. eCollection 2021 Oct. Am Heart J Plus. 2021. PMID: 38550400 Free PMC article. Review.
-
Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19.Res Pract Thromb Haemost. 2023 Aug 8;7(6):102164. doi: 10.1016/j.rpth.2023.102164. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37680312 Free PMC article.
-
The association of APOC4 polymorphisms with premature coronary artery disease in a Chinese Han population.Lipids Health Dis. 2015 Jun 28;14:63. doi: 10.1186/s12944-015-0065-7. Lipids Health Dis. 2015. PMID: 26129832 Free PMC article.
-
Lp(a)/apo(a) modulate MMP-9 activation and neutrophil cytokines in vivo in inflammation to regulate leukocyte recruitment.Am J Pathol. 2014 May;184(5):1503-17. doi: 10.1016/j.ajpath.2014.01.010. Epub 2014 Mar 17. Am J Pathol. 2014. PMID: 24650562 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous